In trial assets

Courtesy of Bell Potter February 2020

Just remember the figures are only for one indication (solid tumours)
The timeline for completion of Phase 2 have blown out by more than 2 years (obviously)


CHEMOTHERAPY IS NOT DEAD AS SOME ON THIS FORUM WOULD LIKE YOU TO BELIEVE

PATENT LIFE
DEP DOCETAXEL POTENTIALLY TILL 2037
DEP CABAZITAXEL POTENTIALLY UNTIL 2044
DEP IRINOTECAN POTENTIALLY UNTIL 2044

REMEMBER THERE ARE PLENTY OF WAY OF EXTENDING PATENT LIFE FOR DRUGS
A relatively straightforward way drug companies can extend a patent is by reformulating a drug – often to simplify dosing or how it's administered. Extended-release versions of drugs are common ways companies reformulate products, for example.




ASSETS

   

INDICATIONS

Solid tumours

STAGE AT LICENSING

Phase 2

LICENSEE

To Be Confirmed

FISCAL YEAR TIMING OF DEAL (EST.)

DEP Docetaxel 2021
DEP Cabazitaxel 2021
DEP Irinotecan 2022

TOTAL DEAL VALUE IN USD MILLIONS (UPFRONT PLUS MILESTONES)

DEP Docetaxel 300
DEP Cabazitaxel 150
DEP Irinotecan 330

UPFRONT

DEP Docetaxel 15
DEP Cabazitaxel 8
DEP Irinotecan 30

MILESTONES

DEP Docetaxel 125
DEP Cabazitaxel 67
DEP Irinotecan 190

COMMERCIAL MILESTONES (USD MILLIONS)


DEP Docetaxel 160
DEP Cabazitaxel 75
DEP Irinotecan 110

ROYALTY RATE (%)

DEP Docetaxel 15%
DEP Cabazitaxel   12%
DEP Irinotecan 17%

NOTE: DEP DOCETAXEL, CABAZITAXEL AND IRINOTECAN DEAL ASSUMPTIONS ARE CONSERVATIVE REFLECTING ITS EARLY STAGE. IT COULD POTENTIALLY HAVE ADDITIONAL VALUE FOR EACH ADDITIONAL INDICATION THAT THE LICENSEE PURSUES. ROYALTIES ARE LIKELY TO BE TIERED FOR EACH DEAL. ASSUME FLAT RATE FOR NOW

Disclosure
I am not a financial advisor. The above information is historical. Comments posted are my opinion only unless stated as facts. DYOR